GlassScriptPhysician profile
Harold F Moessner
NPI 1649226770
$8,562.91
in general payments reported to CMS, 2019-2025
28 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $781 · 2021: $1,413 · 2022: $1,373 · 2023: $1,010 · 2024: $1,133 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,810.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,134.37 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Astrazeneca Pharmaceuticals LP | $1,076.42 | 2019-2025 | Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,073.45 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $973.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $487.85 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Grifols USA, LLC | $411.01 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $407.01 | 2019-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $379.91 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $363.99 | 2019-2025 | |
| Abbvie INC. | $310.35 | 2021-2022 | |
| Optinose US, INC. | $271.88 | 2019-2025 | |
| Amgen INC. | $259.10 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $248.31 | 2025 | Neffy |
| Octapharma USA, INC. | $224.84 | 2021-2025 | Cutaquig |
| Pfizer INC. | $199.59 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $198.00 | 2019-2024 | Xolair |
| Alk-Abello, INC | $134.97 | 2019-2022 | |
| Allergan, INC. | $89.23 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $54.23 | 2019-2023 | Airduo Digihaler |
| Biocryst US Sales Co., LLC | $46.98 | 2022-2024 | Orladeyo |
| Greer Laboratories, INC. | $39.89 | 2019-2025 | Oralair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.40 | 2019-2020 | |
| Lilly USA, LLC | $31.31 | 2024 | Ebglyss |
| Eyevance Pharmaceuticals LLC | $30.26 | 2020 | |
| Ionis Pharmaceuticals, INC. | $25.06 | 2025 | Dawnzera |
| Shire North American Group INC | $22.38 | 2019 | |
| Merck Sharp & Dohme LLC | $18.99 | 2023 | |
| Pharming Healthcare, INC. | $16.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Moessner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.